Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Asso...
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
All six evaluable Phase 1 patients with Danon disease are alive and transplant-free up to age 25 yearsRP-A501 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 expression and =10% reduction in LV mass index at 12 months and sustained through most recent follow up (up to five years)First patient treated shows preliminary evidence of robust protein expression in heart on five-year biopsyAll evaluable patients had reductions in NYHA heart failure (from Class II to Class I) and improvements in KCCQ (median 27-point increase) at 24-54 monthsSubstantial improvements in troponin (median reduction 84%) and BNP (median reduction 57%) observed 24-54 months after treatmentPhase 1 data published in The New England Journal of MedicineInvestor webinar to be held later today at 12:00 p.m. ET CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of gene
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $29.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire
- Rocket Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness Wire
RCKT
Earnings
- 11/7/24 - Beat
RCKT
Sec Filings
- 12/16/24 - Form SC
- 12/16/24 - Form 4
- 12/12/24 - Form 8-K
- RCKT's page on the SEC website